Sverige - svenska - Läkemedelsverket (Medical Products Agency)

novartis sverige ab - budesonid - inhalationspulver, hård kapsel - 200 mikrogram - laktosmonohydrat hjälpämne; sojalecitin hjälpämne; budesonid 200 mikrog aktiv substans - budesonid

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

novartis sverige ab - budesonid - inhalationspulver, hård kapsel - 400 mikrogram - sojalecitin hjälpämne; budesonid 400 mikrog aktiv substans; nykockin hjälpämne; laktosmonohydrat hjälpämne - budesonid

Europeiska unionen - svenska - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklid imaging - terapeutiska radioaktiva läkemedel - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

cheplapharm arzneimittel gmbh - meflokinhydroklorid - tablett - 250 mg - meflokinhydroklorid 274,09 mg aktiv substans; laktos (vattenfri) hjälpämne - meflokin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

2care4 aps - meflokinhydroklorid - tablett - 250 mg - meflokinhydroklorid 274,09 mg aktiv substans; laktos (vattenfri) hjälpämne - meflokin

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pharmachim ab - meflokinhydroklorid - tablett - 250 mg - laktos (vattenfri) hjälpämne; meflokinhydroklorid 274,09 mg aktiv substans - meflokin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - meflokinhydroklorid - tablett - 250 mg - laktos (vattenfri) hjälpämne; meflokinhydroklorid 274,09 mg aktiv substans - meflokin